Biofrontera AG (LTS:0DOL) ROE % Adjusted to Book Value: 59.14% (As of Mar. 2026)


LTS:0DOL Biofrontera AG LTS:0DOL
58 GF Score
Price €2.40
GF Value €2.48
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG ROE % Adjusted to Book Value?

Biofrontera AG LTS:0DOL +0.42% 58 ROE % Adjusted to Book Value is 59.14% as of Mar. 2026. GuruFocus rates LTS:0DOL with a GF Score™ of 58/100 and a GF Value™ of €2.48. The stock has 4 warning signs investors should review.

Biofrontera AG's ROE % for the quarter that ended in Mar. 2026 was 55.00%. Biofrontera AG's PB Ratio for the quarter that ended in Mar. 2026 was 0.93. Biofrontera AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 59.14%.

Biofrontera AG ROE % Adjusted to Book Value Related Terms

Biofrontera AG ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG ROE % Adjusted to Book Value Chart

Biofrontera AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.65 -33.71 -0.49 -2.83 -2.35

Biofrontera AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 -10.23 -0.98 0.26 59.14

LTS:0DOL vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera AG ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's ROE % Adjusted to Book Value falls into.


LTS:0DOL
58GF Score
Biofrontera AG LTS:0DOL
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera AG ROE % Adjusted to Book Value Calculation

Biofrontera AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-23.49% / 10.01
=-2.35%

Biofrontera AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=55.00% / 0.93
=59.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 59.14% mean?
Biofrontera AG (LTS:0DOL) has a ROE % Adjusted to Book Value of 59.14% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biofrontera AG and its competitors.
Is Biofrontera AG's ROE % Adjusted to Book Value too high?
Biofrontera AG's current ROE % Adjusted to Book Value is 59.14%. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Biofrontera AG's ROE % Adjusted to Book Value of 59.14% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current ROE % Adjusted to Book Value is 59.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (LTS:0DOL) has a current ROE % Adjusted to Book Value of 59.14%. The stock's GF Value™ is €2.48, compared to a current price of €2.40 — trading 3.2% below its estimated fair value. The current ROE % Adjusted to Book Value is 59.14%. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current ROE % Adjusted to Book Value is 59.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.40 is trading 3.2% below its estimated GF Value™ of €2.48.

Key valuation signals for LTS:0DOL:

  • ROE % Adjusted to Book Value: 59.14%
  • GF Value™: €2.48 vs. price of €2.40 (3.2% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges B8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for LTS:0DOL

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.40
Price
€2.48
GF Value